Valiant Organics Limited — PPTs, 15-11-2025: Investor Presentation

Valiant Organics reported a strong H1-FY26, with revenue growing 10.2% year-on-year to **361.7 Cr**. The company achieved a profit after tax of **13.9 Cr**, a significant turnaround from a loss last year, with diluted EPS at 4.95. EBITDA margins expanded impressively to 12.69% for H1. For Q2-FY26, revenue was **157.3 Cr**, with profit at **5.7 Cr** and diluted EPS at 2.02, marking a robust recovery from last year's Q2 loss. Gross margins sharply improved to 46% in Q2, driven by better raw material efficiency and product mix, alongside disciplined cost control and reduced finance expenses. Hydrogenation remains the largest revenue-contributing chemistry.

The company focuses on manufacturing high-demand, low-supply specialty chemicals, leveraging integrated operations and a diverse product portfolio. No specific new product launches or capacity expansions were highlighted, nor was any explicit management commentary or future outlook provided in the presentation.